n

( )WHEN ONE MAKES THE MOST OF EVERY POSSIBILITY, LIFE GETS MAXIMIZED.

It takes one word to change the world.P O S S I B I L I T Y .

Possibility is what causes a falling apple

to land upon the idea of gravity.

What sees a 1487-cubic-metre tree

inside a little seed.

What creates windows in walls.

Possibility is what fights a winning battle

against the diseases of the world.

Because when one sees possibilities

in every element and every moment –

and sets out to maximize each one of them –

lives become more beautiful.

The world changes for the better.

At Themis Medicare, we believe this.

( )n

04Meet Our Inspiration

05Our Introduction

06Our Milestones

07Our Strengths

08Our Partners

09Our Manufacturing Solutions

10Our Inventions

11Our Path-breakingMolecule

12Themiseal

14Our Brand Story

13Themiseal-An Unmatched Creation

16Our Global Presence

17Our Compassion

18Our Future

I N D E X

Dear Friends,

I am very pleased to welcome you to Themis Medicare™, one of India’s leading research-based healthcare companies.

At Themis Medicare™, we are dedicated to innovating healthcare. All our e�orts are directed towards developing novel solutions for major unmet medical needs. Over the years, our search for better ways of maintaining and restoring health has resulted in a steady stream of pioneered therapeutic products.

We deliver a unique contribution to better healthcare. Our mission is to reduce su�ering and improve health and quality of life of people all around the world. We have pursued this mission with patience, dedication, imagination and skill, for over 3 decades. Our vision is to develop targeted medicines that o�er patients and physicians better, safer, more cost-e�ective healthcare.

The combined strengths of our API’s and Finished Pharmaceuticals businesses, coupled with our expertise in the emerging and fast growing field of biotechnology equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs.

Our people are our strength who continuously contribute to our mission.

We also take pride in mentioning herewith that we enjoy long-term, close and good understanding with all our business partners.

Once again, welcome to Themis Medicare™, a Company that is dedicated to translating a great vision into reality.

- Dr. Sachin Patel, Ph.D.

M E E T O U R I N S P I R A T I O N

Mission and Vision Statements:

Our mission is to reduce su�ering and improve health and quality of life of people all around the world.

Our vision is to develop targeted medicines that o�er patients and physicians better, safer, more cost-e�ective healthcare.

( )n

O U R I N T R O D U C T I O N

( )n

We are the seekers. We are the ones always in search of possibilities. For we know, in every possibility lies an

innate, latent power to change lives.

We are

In 1969, Dr. Shantibhai D. Patel saw a possibility in science and embarked on a journey to transform a million lives. On his way, he joined hands with Gedeon Richter Ltd., Hungary and maximised his endeavour. Since then, with every remarkable innovation, we have pursued possibilities where others haven’t.

With strong research focus on injectables and drug-delivery systems, we have made wellbeing possible. Emal, world’s first combination of Alpha and Beta components of Arteether for thetreatment of complicated Falciparum Malaria. Etojet, world’s first painless Etrocoxib injection. And of course, world’s first Pain-Free Injectable Diclofenac ( just 1 ml). Every time we believed in the power of possibilities, we’d like to think the world had received some noteworthy creations.

And that’s precisely what defines the DNA of Themis.

O U R M I L E S T O N E S

Establishment of Themis Chemicals (now Themis Medicare) in joint partnership with GEDEON Richter Ltd. , Hungary

1969 :

Themis Chemicals becomes the Second Company in the world and First Company in India to produce Vitamin B12 by non-sterile fermentation.

1971 :

Themis Chemicals is the Second Company in the world and FIRST Company in India to produce Ethambutol Dihydrochloride.

1976 :

Themis Chemicals produces RIFAMPICIN for the FIRST TIME in India

1985 :

Indigenously develops Simvastatin for the first time in Asia

1998 :

Launch of E MAL TM Alpha Beta Arte-ether, a THEMIS-CDRI product, by the Prime Minister Shri Atal Behari Vajpayee on Technology Day

1999 :

Themis Chemicals renamed THEMIS MEDICARE LIMITED

2001 :

Themis Medicare develops and introduces SEPGARD TM , a unique wound healing agent, first time in India.

2002 :

Themis Joint Venture Richter Themis Medicare (India) Pvt. Ltd. commences production

THEMISEAL TM , the unique stops-bleeding gel, arrives in Europe.

Themis Medicare commences operations at Haridwar.

2006:

Long-term partnership signed with Novartis India Limited for exclusive marketing rights of Diclofenac TPM Gel (Voveran TPM Gel) for India

Break through development of Diclofenac 75 mg / ml injection and assigning its exclusive marketing rights to Novartis India Limited under their flagship brand Voveran 75 mg / ml Injection

Introduction of oil free EMAL(Alpha beta arte ether injection) in ampoules, and PFS (Pre-Filled Syringe)

2013 :

TML signs agreement with USA company for developing POC for 5 NDDS injectables

2015 :

( )n

Our Strengths

Partnerships are at the heart of our business. While exploring possibilities in every process, strategy and research, we help our

partners excel.

Our people are our real power

For all the innovations we have attained and milestones we have achieved, the real credit goes to our ever-evolving work force. It’s our strong R&D team who has made all the di�erence with their specialized skills and dedication. The Domestic Marketing and Institutional teams are striving to transform lives with their great talent, while the Export team are taking our endeavours to a new level by supporting the medical fraternity worldwide.

Ready availability of a large range of innovative formulations

With a growing basket of new products, we have always focused on the core issues of critical therapies. It ensures that our partners focus on market expansion and discover new possibilities.

The benefits of our PPT (Patented Platform Technology): • Incisive products that are breakthroughs • Faster product development cycles • Highly detailed documentation of results and trails

On-time deliveries

Our 4 state-of-the-art manufacturing plants: • Have cutting-edge technology and process-driven manufacturing process • Offer skilled factory technicians, who have adherence to production schedules • Ensure deadline-driven, quality-controlled distribution and delivery support

O U R S T R E N G T H S

QC policy / Certified Accreditations

We promise unmatched quality by partnering (on CMO basis)with entities that have certified accreditation.WHO-GMP EUGMP USFDA PICS MHRA

( )n

O U R P A R T N E R S

O U R M A N U F A C T U R I N G S O L U T I O N S

Group companies:

• Themis Medicare Ltd. - Formulations dosage forms – small volume parenterals, tablets, ointments

• Richter Themis Medicare Ltd. - API

• Artemis Biotech Ltd. - API and Fermentation

• Gujarat Themis Biosyn Ltd. - API Synthetic Activity

• Long Island Nutritional Pvt. Ltd. - Nutraceutical Gummies ( )

n

O U R I N V E N T I O N S

With endless research strategies and innovations, we’ve found possibilities in every bright bulb. A committed focus on pain-free injectables and safe products has helped us explore avenues, especially through our NDDS platform technologies.

1. TPM gel technology • A clinically-proven, first-in-class platform technology • Delivers small and large molecules • Non-irritant, patient-friendly and non-invasive

2. Solubilizer technology for turning painful injections into painless injections • Allows oil-free injections (e.g. Hormones) • Significantly reduces the need for use of alcohols in injections (e.g. Diclofenac injection)

With endless research strategies and innovations, we’ve found possibilities in every bright bulb. A committed focus on pain-free injectables and safe products has helped us explore avenues, especially through our NDDS platform technologies.

1. TPM gel technology • A clinically-proven, first-in-class platform technology • Delivers small and large molecules • Non-irritant, patient-friendly and non-invasive

2. Solubilizer technology for turning painful injections into painless injections • Allows oil-free injections (e.g. Hormones) • Significantly reduces the need for use of alcohols in injections (e.g. Diclofenac injection)

Also, we have a remarkable presence in key areas like:

Anti-Tuberculosis | Anti-Malarials | Cardiology| Pain Management | Anti-Infectives | Haematinics

| Health & Nutrition | Anaesthesia | Gynecology | OrthopedicsGel

Breakthroughs that have made inroads in the industry:

1. Anti-malarial

2. NSAIDS

O U R P A T H - B R E A K I N G M O L E C U L E — F E R A C R Y L U M

It also decreases the chance of postoperative infection due to its antimicrobial properties. It has a molecular weight of 50,000-80,000 Daltons because of which it does not get absorbed systemically and has no adverse e�ects on the liver, kidney,

adrenals, cardiovascular hematopoietic system.2

Feracrylum, is a unique topical hemostatic agent that has revolutionized the field of hemostasis and has become a dependable companion in various surgical procedures.1 Feracrylum is an incomplete ferrous salt (II and III) of

polyacrylic acid. It is used to control oozing in various surgical procedures. It has good hemostatic property with no local side-e�ects and is cost- e�ective.2

References:

1) Lahoti BK, Aggarwal G, Diwaker A et al., Hemostasis during hypospadias surgery via topical application of feracrylum citrate: A randomized prospective study. Journal of Indian Association of Pediatric Surgeons. 2010; 15(3): 8789.

2) Laddha AK, Mulla M, Sharma SS, Lahoti BK, Mathur R. A prospective comparison of topical feracrylum citrate versus adrenaline as haemostatic agent in hypospadias surgery in children. Afr J Paediatr Surg 2014;11:215-8.

Forms an insoluble poly complex when it comes in

contact blood to form a coagulum in 30sec that helps control bleeding

Protects the wound by actingas a physical barrier,

decreasing local infection

Provides moisture forhealing that helps in

regeneration of the cells

Mode of action of Feracrylum

References:

1) Moenadjat Y, Setiabudy R, Astrawinata DAW et al., The safety and efficacy of feracrylum as compared to silver sulfadiazine in the management of deep partial thickness burn: A clinical study report. Med J Indones. 2008; 17: 259-71.2) Data on file

T H E M I S E A L

Themiseal is a 3-in-1 solution in wound management, which is:

Themiseal contains feracrylum that provides an optimal environment to facilitate wound healing, decrease the rate of wound infection, and appears to be the trend of wound management in the future.1

Aids natural healing by non-specific coagulation and resulting hemostasis

No toxin deposition

Biocompatible & Biodegradable

It’s bio -safeFor coagulation disorders

Prevents entry of bacteria(completely eliminates chance of infection)

Quick Hemostasis that speeds up the healing process

Free from animal protein

It’s patient-friendlyForms complexes when in contact with blood, exerting haemostatic action

Strong adherence on wound site

Does not enter systemic circulation

Restores tissue integrity & functions

Protection to nerve endings

Prevents blood loss

It’s innovative and safe

T H E M I S E A L – A N U N M A T C H E D C R E A T I O N

Themiseal’s strengths

Aids natural healing

Seals the wound site to form barrier against foreign bodies

Rapidly and e�ectively controls bleeding and infection

Excellent adherence at the bleeding surface

Available in multiple delivery options and variants

Compatible in all types of patients and all types of wounds

Competitors’ weaknesses

Unavailability of multiple variants

Controls minor bleeding and cannot exert antimicrobial action

Average or no wound site adherence

Can provoke allergic reactions and subsequent delayed healing

Themiseal is available in 4 variants:

O U R B R A N D S T O R Y

1. Themiseal Solution (Feracrylum 1% w/v)

Key characteristics • A haemostatic and antiseptic solution to control intra, and post-operative oozing and ensure clear field of vision.• Reduces frequency of cauterization and the need for blood transfusion• Used for Intra and post-operative control of oozing, irrigation of surgical or burn site, and is used after debridement

2. Themiseal Gel (Feracrylum 3%w/w)

Key characteristics • Themiseal gel is superior than povidone-iodine• It reduces peripheral oedema and ensures better wound healing• Used in treatment of Cuts, Lacerated Wounds, Crush injuries, Decubitis Wounds, Chemical, Thermal and Surgical wounds, Post-operative wounds, Excoriated wounds, Abrasions , Episiotomy Cuts

O U R B R A N D S T O R Y

3. Themiseal Mouth Gargle (Feracrylum 1%w/v)

Key characteristics • Themiseal is the only mouth wash that o�ers benefit of quick haemostatis as well as anti-microbial action and is not just a mouth freshener. • Superior to commonly available mouth gargles.• Used in controlling capillary bleeding during minor oral surgeries, like tooth extraction, and bleeding gums

4. Themiseal Tulle (Feracrylum 3%w/w)

Key characteristics • Themiseal gauze ensures faster wound healing• Provides smoother and cosmetically acceptable healed surface• Used to stop bleeding quickly in traumatic conditions, lacerations, abrasions, crash injuries. In thermal injuries such as Burns, scalds, Ulcerative conditions such as Varicose veins, Diabetic Decubitis, Tropical Ulcers and skin grafts.

Themiseal has spread its wings across

O U R G L O B A L P R E S E N C E

Kenya Nigeria Vietnam Philippines India Indonesia Jordan Saudi Kuwait Spain

Installation of Sanitary Pad Manufacturing Machine We are on a mission to create better conditions for women in our country. In this endeavour, we have partnered with The Bombay Mothers & Chidren Welfare Society, an NGOdedicated to development of rural India, and set up asanitary napkin manufacturing unit in the village ofRajgurunagar in Maharashtra.

O U R C O M P A S S I O N

From market goals to mankind, we have come a long way. By exploring areas that are related to our strengths, we have made sure we o�er support to make this world a better place. With great dedication and thoughtful solutions, we are striving to bring a change – one initiative at a time.

Mobile E-learning Unit

In an e�ort to take the quality of education in rural areasto a new level, we have planned to fund a mobileE-learning unit. Our contribution is in the purchase of the vehicle that will be used to transport computer units to aid E-Learning.

Future Plans:

E-learning Module: Assistance in increasing the accessibility of E-learning module to more no. of schools in the village of Rajgurunagar and other villagessurrounding it.

Providing cycles as a mode of transport: Where childrenhave to walk 5kms to reach school and villagers have to carry water from far locations, a village like Rajgurunagar was in dire need of support. Hence, we have decided to o�er them cycles to help improve their routine and make their life easy.

Group companies:

• Themis Medicare Limited• Gujarat Themis Biosyn Limited• Artemis Biotech Limited• Richter Themis Medicare Limited• Long Island Nutritional Pvt Limited

O U R F U T U R E

n

With a passion to look for new possibilities, Themis continues to focus on unmet medical needs. Our products will arrive soon to make a di�erence.

12 OphthalmicRangeproducts

9products

Anti-cancerrange

7products

Anaestheticsrange

6products

Pain Managementrange

4products

Anti-malarialsrange

3products

Hormones

nOpen up a world of

P O S S I B I L I T I E S

Corporate O�ce :Themis Medicare Ltd., 11/12 Udyognagar ,

S. V. Road , Goregaon (W), Mumbai 400104, India,Tel : 91-22-67607080,Fax : 91-22-28746621

Web : www.themismedicare.com

Registered O�ce address:Themis Medicare Limited,Plot No. 69-A G.I.D.C,VAPI - 396195, Dist. Valsad,State – GujaratPhone : 0260-2431447

P R O D U C T O F F E R I N G S

Products Dosage FormSr. No.

Diclofenac Sodium Hcl

Diclofenac Sod. + Dicylomine Hcl

Etoricoxib Hcl

Cisatracurium

Dexmeditomedine Hcl

Palonosetron Hcl 250 mcg

Palonosetron Hcl 75 mcg

Lignocaine Hcl

Lignocaine AD (Lignocaine + Adrenaline)

Bupivacaine Heavy

Bupivacaine Hcl

Ketamine Hcl

Aceclofenac Hcl

Glycopyrrolate Bromide + Neostigmin Methylsulphate*

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

Injectables

Injectables(NDDS)

Progestrone (Oil free)

21

22

23

24

25

26

Hormone Injectables

NDDS Gel

Gels

Neostagmine Methylsulphate

Medazolam

Artemether

a/b Arteether

Injectables

Artemether + Lumefantrine

Artemether + Lumefantrine

Artemether + Lumefantrine

Etoricoxib Hcl

Oral Solids

Diclofenac Sodium Hcl TPM

Diltiazem Hcl

Tioconazole

27

28

29

Feracrylum Gel

Feracrylum Mouth Gargle

Feracrylum Solution

Medical Device(CE)

04Meet Our Inspiration

05Our Introduction

06Our Milestones

07Our Strengths

08Our Partners

09Our Manufacturing Solutions

10Our Inventions

11Our Compassion

12Our Future

I N D E X